Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Drug: Placebo
Drug: Theophylline

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02273440

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin (ER)
Drug: Persantin
Drug: Acetyl salicylic acid (ASA)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02273505

Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS - rising dose
Drug: Placebo

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT02273414

Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Other: low fat meal
Other: high fat meal

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273427

Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Asasantin®

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02273479

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER, new formulation
Drug: Asasantin ER, present commercial formulation

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273531

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 11054 CL
Drug: Placebo

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02273401

Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Desipramine tablet
Drug: Crobenetine infusion
Drug: Placebo infusion

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02273466

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Asasantin ER - commercial formulation
Drug: Asasantin ER (new formulation - low)
Drug: Asasantin ER (new formulation - high)
Drug: Asasantin ER (new formulation - medium)

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02273544

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER, new formulation II
Drug: Asasantin ER, new formulation I
Drug: Asasantin ER, present commercial formulation

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02273518

AI-Powered Research

Premium Access

Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers

Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers